Breast Cancers Treatments: Overcoming Drug Resistance

Dear Colleagues,

Despite progress in breast cancer treatment, a considerable problem facing clinicians is the development of drug resistance. Therefore, it is very important to elucidate the several molecular pathways leading to drug resistance that metastatic breast cancer orchestrates. Hence, investigating the molecular mechanisms involved in drug resistance is necessary to reduce the adverse effects of treatment and develop new strategies for improving diagnosis and prognosis, which could result in a better response to therapy. The goal of this Special Issue is to help develop a better understanding of the signaling pathways and cross talks that underly the different intracellular responses. This will assist in devising specific interventions to abrogate or inhibit the signaling mechanisms involved in causing resistance to therapy in various subtypes of breast cancers.

The scope of this Special Issue provides a platform to all researchers in the field of breast cancer to present their work in elucidating the mechanisms that lead to drug resistance, as well as the drugs or combinations of drugs that are under development to address this resistant mechanism. The research could encompass basic and translational studies involving various bio-informatic avenues confirmed by wet lab experiments. It is preferable that the proposed work addresses mechanisms with novel approaches, which could result in clinical trials leading to therapy. The work could involve genetic, epigenetic, genomic, or proteomic studies that are well substituted and complemented by confirmatory experiments with statistical significance.

Dr. Eswar Shankar
Dr. Balaji Chandrasekaran
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.